Pluri (PLUR) vs Tempest Therapeutics (TPST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pluri (PLUR) has outperformed Tempest Therapeutics (TPST) over the past year, losing 75.5% versus a loss of 93.0%. Over five years, PLUR leads with a -95.2% price change compared with -99.6% for TPST. Tempest Therapeutics is the larger company by market cap ($13.0 million vs $12.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PLUR | TPST |
|---|---|---|
| Share price | $1.00 | $0.77 |
| Market cap | $12.61M | $13.01M |
| 1-day change | -3.85% | -2.70% |
| YTD return | -66.56% | -73.17% |
| 1-year return | -75.49% | -92.99% |
| 5-year return | -95.23% | -99.60% |
| EPS (TTM) | $-2.44 | $-3.93 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.87 | $12.23 |
| 52-week low | $0.85 | $0.743 |
| Distance from 52-week high | -79.47% | -93.70% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +809.09% |
| Average volume | 24.97K | 2.60M |
| Shares outstanding | 12.61M | 16.89M |
| Employees | 92 | 4 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PLUR has outperformed TPST by 17.5 percentage points over the past year.
About Pluri
PLUR stock →Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and an immunotherapy platform.
Healthcare · Biotechnology · 92 employees
About Tempest Therapeutics
TPST stock →Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers.
Healthcare · Biotechnology · 4 employees
PLUR vs TPST FAQ
Which is bigger, Pluri or Tempest Therapeutics?
Tempest Therapeutics (TPST) is larger, with a market capitalization of $13.01M compared with $12.61M for Pluri (PLUR).
Which stock has performed better over the past year, PLUR or TPST?
PLUR returned -75.49% over the past 12 months, compared with -92.99% for TPST (price return, excluding dividends). Past performance does not predict future results.
Are Pluri and Tempest Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.